52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Merck Says U.S. FDA Accepts For Priority Review The Supplemental BLA For Vaxneuvance
Merck's Keytruda Approved In Japan In Combination With Chemotherapy For Esophageal Carcinoma
Merck Says FDA Accepts Submission Of sNDA For Lynparza As Treatment Breast Cancer, Grants Priority Review
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.
Biotechnology & Drugs
2000 Galloping Hill Rd
Kenneth C. Frazier
Executive Chairman of the Board
Robert M. Davis
President, Chief Executive Officer, Director
Chief Financial Officer, Executive Vice President
Franklin K. Clyburn
President, Human Health, Head of Human Health Commercial and Marketing
Dean Y. Li
President - Merck Research Laboratories
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Belgium is in talks with U.S.-based Merck & Co Inc to buy 10,000 doses of its COVID-19 antiviral pill jointly developed with Ridgeback Biotherapeutics, the country's federal health minister said on Wednesday.
A panel of expert advisers to the U.S. Food and Drug Administration on Tuesday narrowly voted to recommend the agency authorize Merck & Co's antiviral pill to treat COVID-19.
Canada, seeking to halt the spread of the Omicron coronavirus variant, will require people arriving by air from all nations except the United States to take a COVID-19 test, Health Minister Jean-Yves Duclos said on Tuesday.
The Canadian government said on Tuesday it was in advanced talks with Pfizer Inc and Merck & Co Inc regarding a purchase agreement for COVID-19 antiviral drugs.
A panel of outside advisers to the U.S. Food and Drug Administration on Tuesday voted in favor of authorizing Merck & Co oral COVID-19 pill, saying the drug's benefits outweigh its potential risks.
Merck & Co Inc's experimental COVID-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on Tuesday.
A panel of expert advisers to the U.S. Food and Drug Administration will vote later on Tuesday on whether to recommend authorization of Merck & Co's antiviral pill to treat COVID-19.
Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.
* U.S. FDA PUBLISHES BRIEFING DOCUMENTS ON MERCK & CO INC'S COVID-19 PILL Source text: (https://bit.ly/311Toua) Further company coverage:
Merck & Co Inc said on Friday its experimental COVID-19 pill reduced the risk of hospitalization and death by 30% in a study, according to data from all the patients enrolled in a late-stage study. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
Drugmakers Pfizer Inc and MSD, known as Merck & Co Inc in North America, have agreed to give licenses to firms in Vietnam to produce COVID-19 treatment pills, Vietnam's ministry of health said on Friday.
The European Union's drug regulator said on Tuesday it has started reviewing U.S. drugmaker Merck & Co Inc's experimental COVID-19 antiviral pill for adults following an application and could issue an opinion "within weeks."
The Swiss government said on Tuesday it had reserved up to 8,640 doses of Merck's COVID-19 drug Molnupiravir.
The European Union's drug regulator has issued advice on using Merck's COVID-19 pill for adults and began a review of a rival tablet from Pfizer to help member states decide on quick adoption ahead of any formal EU-wide approval.
The Biden administration is looking at ways to broaden access to potential COVID-19 antiviral pills when supply increases in the coming months, the Wall Street Journal reported on Friday, citing a person familiar with the plans.
The European Union's drug regulator on Friday advised that an experimental COVID-19 pill from Merck should be given within five days of first symptoms to treat adults who do not need oxygen support and are at risk of their disease worsening.
The European Union's drug regulator on Friday advised https://www.ema.europa.eu/en/news/ema-issues-advice-use-lagevrio-molnupiravir-treatment-covid-19 Merck and Ridgeback Biotherapeutics' experimental COVID-19 pill can be given within five days of first symptoms to treat...
Pfizer Inc said on Thursday the U.S. government would pay $5.29 billion for 10 million courses of its experimental COVID-19 antiviral drug, as the country rushes to secure promising oral treatments for the disease.
The European Medicine Agency's review to approve Merck's antiviral pill molnupiravir, developed with Ridgeback Therapeutics, is set to conclude by the end of the year, the regulator's head of vaccine strategy said on Thursday.
Italy's COVID-19 Special Commissioner was given a mandate by the health ministry to acquire 50,000 courses of each of Merck's and Pfizer's COVID-19 antiviral drugs, his office said in a statement.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.